Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
Despite consistent evidence that HPV vaccines are safe and effective, a new study shows that more parents are citing concerns about their safety. Researchers cautioned that efforts are needed to counter this trend and improve vaccination rates.
-
In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
-
New treatments are helping more people with advanced or metastatic cancer live longer. At a recent NCI conference, survivors and researchers came together to discuss how to better address the needs of those living with metastatic cancer.
-
Trial results show patients who received the immunotherapy pembrolizumab (Keytruda) after surgery to remove high-risk stage II melanomas were less likely to have the cancer come back than those who received no treatment after surgery.
-
In a large clinical trial, women with HR-positive, HER2-negative metastatic breast cancer treated with ribociclib (Kisqali) and letrozole (Femara) as their initial treatment lived approximately 1 year longer than women treated with letrozole only.
-
Women with early-stage breast cancer who had one or both breasts surgically removed (a unilateral or bilateral mastectomy) had lower scores on a quality-of-life survey than women who had breast-conserving surgery, a new study has found.
-
Women are far more likely than men to be diagnosed with small thyroid cancers that probably would have never caused problems during their lifetime, a new study finds. The results may help explain why thyroid cancer seems to be more common in women.
-
Aneuploidy—when cells have too many or too few chromosomes—is common in cancer cells, but scientists didn’t know why. Two new studies suggest that aneuploidy helps the cells survive treatments like chemotherapy and targeted therapies.
-
FDA has approved belzutifan (Welireg) to treat adults with von Hippel-Lindau disease (VHL) who have tumors of the kidney, brain, nervous system, or pancreas. The drug may help these patients avoid or delay surgery by shrinking their tumors.
-
NCI Director Dr. Ned Sharpless discusses progress against childhood cancers, like CAR T-cell therapy and collecting more comprehensive data on children and adolescents with cancer, and the need to better address disparities in childhood cancer.